Key interactions of the mutant HIV-1 reverse transcriptase/efavirenz: an evidence obtained from ONIOM method

被引:13
|
作者
Boonsri, Pornthip [1 ,2 ,3 ]
Kuno, Mayuso [4 ]
Hannongbua, Supa [1 ,2 ,3 ]
机构
[1] Kasetsart Univ, Fac Sci, Dept Chem, Bangkok 10900, Thailand
[2] Kasetsart Univ, Ctr Nanotechnol KU, Bangkok 10900, Thailand
[3] Kasetsart Univ, NANOTEC Ctr Excellence, Bangkok 10900, Thailand
[4] Srinakharinwirot Univ, Fac Sci, Dept Chem, Bangkok 10110, Thailand
关键词
IMMUNODEFICIENCY-VIRUS TYPE-1; QUANTUM-CHEMICAL CALCULATIONS; WILD-TYPE; K103N MUTANT; CRYSTAL-STRUCTURES; EFAVIRENZ DMP-266; STRUCTURAL BASIS; DRUG-RESISTANCE; BINDING-ENERGY; HIGHLY POTENT;
D O I
10.1039/c1md00162k
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Two-layered ONIOM calculations were performed in order to compare the binding of efavirenz (EFV) to the HIV-1 RI binding pocket of both wild type (WT) and K103N enzymes. The K103N mutation reduces the binding affinity of the inhibitor by 5.81 kcal mol(-1) as obtained from the ONIOM2 (B3LYP/6-31G(d,p):PM3) method. These indicate that the loss of binding energy to K103N mutation can attribute to a weakened attractive interaction between the drug and residues surrounding in the binding pocket. The deformation of the K103N binding pocket requires more energy for structural rearrangement than that of the WT by approximately 4.0 kcal mol(-1). Moreover, the pairwise energies perfectly demonstrate that the K103N mutation affects on the loss of the interaction energy. In addition, the main influences are due to residues surrounding in the binding pocket; K101, K102, S105, V179, W229, P236 and E138. In particular, two residues; K101 and S105, established hydrogen bondings with the inhibitor. ONIOM calculations, resulting in the details of binding energy, interaction energy and deformation energy can be used to identify the key interaction and structural requirements of more potent HIV-1 RT inhibitor.
引用
收藏
页码:1181 / 1187
页数:7
相关论文
共 50 条
  • [21] HIV-1 reverse transcriptase inhibitors
    Lloyd, AW
    DRUG DISCOVERY TODAY, 1996, 1 (03) : 122 - 122
  • [22] HIV-1 reverse transcriptase inhibitors
    Yazan El Safadi
    Valérie Vivet-Boudou
    Roland Marquet
    Applied Microbiology and Biotechnology, 2007, 75 : 723 - 737
  • [23] 4,1-Benzoxazepinone analogues of efavirenz (Sustiva™) as HIV-1 reverse transcriptase inhibitors
    Cocuzza, AJ
    Chidester, DR
    Cordova, BC
    Klabe, RM
    Jeffrey, S
    Diamond, S
    Weigelt, CA
    Ko, SS
    Bacheler, LT
    Erickson-Viitanen, SK
    Rodgers, JD
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (11) : 1389 - 1392
  • [24] Synthesis and evaluation of benzoxazinones as HIV-1 reverse transcriptase inhibitors.: Analogs of Efavirenz (SUSTIVA™)
    Patel, M
    McHugh, RJ
    Cordova, BC
    Klabe, RM
    Erickson-Viitanen, S
    Trainor, GL
    Ko, SS
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (22) : 3221 - 3224
  • [25] RECOGNITION OF MUTANT TRANSFER RNA(LYS) BY HIV-1 REVERSE-TRANSCRIPTASE
    LI, XQ
    LAU, R
    YEN, T
    RULAND, C
    STEPHENS, D
    ROSENBLATT, JD
    BLOOD, 1993, 82 (10) : A412 - A412
  • [26] INTERACTIONS OF THE HIV-1 REVERSE-TRANSCRIPTASE AZT-RESISTANT MUTANT WITH SUBSTRATES AND AZT-TP
    POKHOLOK, DK
    GUDIMA, SO
    YESIPOV, DS
    DOBRYNIN, VN
    RECHINSKY, VO
    KOCHETKOV, SN
    FEBS LETTERS, 1993, 325 (03) : 237 - 241
  • [27] Mass Spectrometric Characterization of HIV-1 Reverse Transcriptase Interactions with Non-nucleoside Reverse Transcriptase Inhibitors
    Thammaporn, Ratsupa
    Ishii, Kentaro
    Yagi-Utsumi, Maho
    Uchiyama, Susumu
    Hannongbua, Supa
    Kato, Koichi
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2016, 39 (03) : 450 - 454
  • [28] Modeling of activity of efavirenz with the mutant of HIV reverse transcriptase using variable connectivity indices
    Zhong, CL
    He, JT
    Xia, ZQ
    Li, YJ
    QSAR & COMBINATORIAL SCIENCE, 2004, 23 (08): : 650 - 654
  • [29] Molecular and Crystal Structure of Efavirenz, a Potent and Specific Inhibitor of HIV-1 Reverse Transcriptase, and Its Monohydrate
    Ravikumar, Krishnan
    Sridhar, Balasubramanian
    MOLECULAR CRYSTALS AND LIQUID CRYSTALS, 2009, 515 : 190 - 198
  • [30] New Efavirenz Derivatives and 1,2,3-Triazolyl-phosphonates as Inhibitors of Reverse Transcriptase of HIV-1
    Costa, Carolina C. P.
    Boechat, Nubia
    Bastos, Monica M.
    da Silva, Fernando de C.
    Marttorelli, Andressa
    Souza, Thiago M. L.
    Baptista, Mayara S.
    Hoelz, Lucas V. B.
    Cafffarena, Ernesto R.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2018, 18 (17) : 1494 - 1505